Search Results

You are looking at 1 - 10 of 177 items for :

  • "acute myeloid leukemia" x
Clear All
Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman and Eunice S. Wang

Overview I n 2010, approximately 12,330 people were diagnosed with and 8950 died of acute myeloid leukemia (AML). 1 As the population ages, the incidence of AML, along with myelodysplasia, seems to be rising. Equally disturbing is the

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Salil Goorha, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, Eunice S. Wang, Maoko Naganuma and Kristina M. Gregory

-body irradiation or radioimmunotherapy) given before autologous stem cell transplantation, may also increase the risk of therapy-related MDS/AML. 12 , 13 NCCN Clinical Practice Guidelines in Oncology : Acute Myeloid Leukemia, Version 2.2012 Version 2

Full access

Margaret R. O'Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Vijaya Bhatt, Dale Bixby, William Blum, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Steven D. Gore, Aric C. Hall, Patricia Kropf, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Joseph O. Moore, Rebecca Olin, Deniz Peker, Daniel A. Pollyea, Keith Pratz, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Matthew Wieduwilt, Kristina Gregory and Ndiya Ogba

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults, and it

Full access

Margaret R. O’Donnell

Bone Marrow Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, and Chair of the Acute Myeloid Leukemia (AML) Panel of NCCN. Thus, the changes in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML

Full access

Margaret R. O’Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Kristina M. Gregory and Maoko Naganuma

otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN Guidelines Insights : Acute Myeloid Leukemia, Version 2

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger and James O. Armitage

+ -AML Identify the evidence supporting clinicopathologic distinction between Ph + -AML and chronic blast phase CML Discuss the role of SCT in the treatment of Ph + -AML Philadelphia chromosome-positive acute myeloid leukemia (Ph

Full access

Martin Tallman

In 2018, state-of-the-art treatment for acute myeloid leukemia (AML) is characterized by 6 features: Defined by cytogenetic and molecular interactions, Intensified induction/less intensive consolidation, Increased importance of minimal

Full access

Alison R. Walker and Guido Marcucci

For patients with acute myeloid leukemia (AML), acquired chromosomal abnormalities present at diagnosis are the most important independent predictors of complete remission, disease-free survival, and overall survival. 1 - 3 Chromosomal analysis

Full access

Christa Meyer, Lih-Wen Mau, Elizabeth A. Murphy, Ellen M. Denzen, Ellyce Hayes, Darlene Haven, Heather Moore, Jackie Foster, Jaime M. Preussler and Linda J. Burns

Background Hematopoietic cell transplantation (HCT) is an underused therapy for patients with acute myeloid leukemia (AML). 1 Because HCT is performed only at select hospitals in the United States, it is critical to understand physician referral

Full access

Holbrook E. Kohrt and Steven E. Coutre

Dick JE . Acute myeloid leukemia . Hematology Am Soc Hematol Educ Program 2001 : 62 – 86 . 4. Appelbaum FR Gundacker H Head DR . Age and acute myeloid leukemia . Blood 2006 ; 107 : 3481 – 3485 . 5. Leith CP Kopecky KJ